Two of the implanted valves lasted a full year as the animals matured into adult sheep, demonstrating that it might be possible to treat children with valve replacements that grow along with them.

Researchers remuscularize the heart after cardiac infarction with stem cell-derived cardiomyocytes and ready-made microvessels.

The multifarious nature of the damage means treatments for cardiac issues during infection will require tailored approaches.

Images of the players’ hearts showed signs of inflammation consistent with myocarditis, a rare but potentially fatal condition.

There is little evidence that antihypertensive drugs worsen COVID-19, and scientists are instead exploring the idea that such medications—or their downstream effects—may actually alleviate symptoms.

A bioengineered heart made of pig and synthetic tissues beats like the real thing.

A growth factor treatment helps improve cardiac functioning after heart attack in pigs.

To advance the possibility of off-the-shelf cardiac cell therapies, scientists devise an engineered cardiac stem cell that avoids stimulating a detrimental immune attack.

A study in mice reveals that stem cell transplants, currently in clinical trials, may not actually require the cells.

Slowing to just two beats per minute, the animals’ heart rate shows how they survive plunging far below the ocean’s surface to eat.

A clinical trial is underway to see if suspended animation, in which the body is cooled to 10–15 °Celsius, could slow patients’ decline and give doctors time to operate.

Scientists show the approach can kill cells that cause hardening of heart tissue in mice.

A case study of a family demonstrates that different genetic mutations from the two parents cause severe heart disease symptoms in the children.

Patients in a study of catheter ablation who showed signs of more injury to nerve cells and glia in the heart had fewer symptoms after the treatment.

CRISPRed heart muscle cells from humans gain the ability to make a protein missing in Duchenne muscular dystrophy.

By zooming in on a developing mouse heart, scientists are studying whether defects in vasculature contribute to a thin muscle wall.

It’s the latest fallout from an investigation by Harvard and Brigham and Women’s into work overseen by Piero Anversa.

A trial to test whether so-called c-kit cardiac stem cells, first reported by Piero Anversa, could help patients with chronic heart failure has been halted in light of suspicion surrounding his work.

Harvard and Brigham and Women’s Hospital disavow the work by former faculty member Piero Anversa.